Revolution Medicines RVMD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Revolution Medicines (RVMD) Core Market Data and Business Metrics
Latest Closing Price
$34.6Price-Earnings Ratio
-9.66Total Outstanding Shares
185.91 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
700 Saginaw Dr, Redwood City, CA, 94063
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,428,391 Shares | 11.66 | 3/14/2025 | 16,652,995 Shares |
| 1,326,206 Shares | 11.94 | 2/28/2025 | 15,839,448 Shares |
| 1,166,240 Shares | 12.8 | 2/14/2025 | 14,924,861 Shares |
| 1,399,531 Shares | 11.37 | 1/31/2025 | 15,912,962 Shares |
| 1,345,829 Shares | 12.33 | 1/15/2025 | 16,592,904 Shares |
| 1,272,819 Shares | 12.8 | 12/31/2024 | 16,292,256 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $959.41 Million |
| Net Cash Flow, Continuing | $-152.42 Million |
| Net Cash Flow From Investing Activities, Continuing | $-554.39 Million |
| Net Cash Flow | $-152.42 Million |
| Net Cash Flow From Operating Activities, Continuing | $-557.44 Million |
| Net Cash Flow From Financing Activities, Continuing | $959.41 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Current | $-15,000 |
| Income Tax Expense/Benefit | $-753,000 |
| Nonoperating Income/Loss | $88.68 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-600.09 Million |
| Income/Loss From Continuing Operations Before Tax | $-600.85 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-599.32 Million |
| Other Comprehensive Income/Loss | $777,000 |
| Comprehensive Income/Loss Attributable To Parent | $-599.32 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $2.33 Billion |
| Intangible Assets | $56.67 Million |
| Equity | $2.27 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Current Liabilities | $163.91 Million |
| Noncurrent Liabilities | $129.18 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||